HUMAN FACILITATING CELLS
The present disclosure relates to human facilitating cells (hFC), and methods of isolating, characterizing, and using such hFCs.
1 . A cellular composition comprising at least about 30% human facilitating cells (hFCs), wherein said hFCs comprise cells having a phenotype of CD8+/alpha beta TCR−/CD56 dim/neg and cells having a phenotype of CD8+/alpha beta TCR−/CD56 bright .
2 . The cellular composition of claim 1 , wherein said cells having a phenotype of CD8+/alpha beta TCR−/CD56 dim/neg are predominantly CD3 epsilon+/CD19−.
3 . The cellular composition of claim 1 , wherein said cells having a phenotype of CD8+/alpha beta TCR−/CD56 bright are predominantly CD3 epsilon−/CD19+.
4 . The cellular composition of claim 1 , wherein said hFCs comprise cells having a phenotype of CD8+/alpha beta TCR−/delta gamma TCR+/CD3 epsilon+/CD19+.
5 . The cellular composition of claim 1 , wherein said hFCs comprise cells having a phenotype of CD8+/alpha beta TCR−/B220+/CD11c+/CD11b−.
6 . The cellular composition of claim 1 , wherein about 48% of said hFCs are CD8+/alpha beta TCR−/CD3 epsilon+, about 33% of said hFCs are CD8+/alpha beta TCR−/CD19+, about 44% of said hFCs are CD11c+, about 40% of said hFCs are CD11b+, about 42% of said hFCs are Foxp3, and about 30% of said hFCs are HLA-DR.
7 . The cellular composition of claim 6 , wherein about 25% of said hFCs are CD8+/alpha beta TCR−/IFN-gamma and about 31% of said hFCs are CD8+/alpha beta TCR−/CXCR4.
8 . The cellular composition of claim 1 comprising at least about 40% of the hFCs.
9 . The cellular composition of claim 1 comprising at least about 50% of the hFCs.
10 . The cellular composition of claim 1 comprising at least about 60% of the hFCs.